---
title: "KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305683102.md"
description: "Zenkuda’s DAYBREAK results supported six-month dosing for many patients, and its three-indication BLA was targeted for year-end 2026. KSI-101’s PEAK 1 readout was expected before Christmas, while KSI-501’s DME Phase III program was accelerating.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-11-16T14:02:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305683102.md)
  - [en](https://longbridge.com/en/news/305683102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305683102.md)
generator: "portal-rs"
---

# KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones

Zenkuda’s DAYBREAK results supported six-month dosing for many patients, and its three-indication BLA was targeted for year-end 2026. KSI-101’s PEAK 1 readout was expected before Christmas, while KSI-501’s DME Phase III program was accelerating.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [KOD.US](https://longbridge.com/en/quote/KOD.US.md)

## Related News & Research

- [Did Phase 3 Eye Drug Results Just Shift Kodiak Sciences (KOD) Investment Narrative?](https://longbridge.com/en/news/305493238.md)
- [Kodiak Sciences GAAP EPS of -$1.05 beats by $0.01](https://longbridge.com/en/news/305374957.md)
- [Kodiak Sciences (KOD) Could Be 23% Undervalued On Its Retina Pipeline Story](https://longbridge.com/en/news/304752600.md)
- [MRNA: Intismeran advances toward melanoma launch as cancer trials expand](https://longbridge.com/en/news/305969014.md)
- [Is ServiceNow (NOW) Trading At Too High A Premium For Earnings?](https://longbridge.com/en/news/306039339.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**